At a Glance
Ajanta Pharma is the kid in your class who quietly aces every test while you’re busy copying from the neighbor. With a market cap of ₹33,666 crore and an ROE of 24.9%, this mid-cap pharma player punches above its weight. Its Q1 FY26 numbers scream stability: sales ₹1,303 crore, net profit ₹255 crore, and EPS ₹20.44. Throw in a debt-free balance sheet, a healthy dividend payout, and a penchant for launching “first-to-market” drugs, and you’ve got a company that’s less pharma, more farmer—always harvesting profits.
Introduction
Picture a company that doesn’t just sell medicines; it sells hope in blister packs. Ajanta Pharma has been compounding investor wealth while you were busy compounding chemistry formulas. From cardiology to ophthalmology, they’ve got a pill for everything except your broken heart after seeing their stock at 8.8x book value.
The stock trades at a P/E of 36.2—expensive? Sure. Just like those overpriced protein shakes, but hey, the market still gulps it down. The company recently announced a buyback and expanded capacity, signaling they’re not just resting on their pill bottles.
Business Model (WTF Do They Even Do?)
Ajanta specializes in branded generics across India (31% revenue), emerging markets (Africa and Asia), and the regulated US/European markets. Their superpower? Launching niche, first-to-market drugs where competition is still taking a nap. With 500+ products, half being first to market, Ajanta isn’t just playing the game—it’s rewriting the rulebook.
Revenue streams are well diversified: branded generics dominate, with ophthalmology, dermatology, cardiology, and pain management being the key therapy areas. They also have a strong presence in anti-malarials for Africa—saving lives while saving profits.
Financials Overview
Here’s where Ajanta flexes its financial muscles:
- Revenue (TTM): ₹4,806 crore
- Net Profit (TTM): ₹930 crore
- EBITDA: ₹1,280
